Nearly a quarter of the world’s leading pharmaceutical companies consider that diversifying away from selling medicines while expanding sales in emerging markets are the most promising ways to sustain growth, a survey has found.

These fresh strategies meet intensifying industry and investor concerns about patent expiry, pressure on pricing and reimbursement, and difficulties in launching drugs.